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doi:10.1Objective: This study compared outcomes between thoracic endovascular aortic repair and conventional open
surgical and medical therapies for acute complicated type B aortic dissection.
Methods: From 2002 to 2010, a total of 170 patients with type B aortic dissections were retrospectively identified
from the University of Pennsylvania aortic database. Of these 170 patients, 147 had acute type B aortic dissections
(uncomplicated 70, complicated 77). For patients with acute complicated type B aortic dissections, management in-
cluded thoracic endovascular aortic repair (group A) or conventional open surgical and medical therapies (group B).
Results: In the 77 patients with acute complicated type B aortic dissections, thoracic endovascular aortic repair
(group A) was performed in 45 patients (59%). In group B, 20 patients (26%) underwent open surgical repair and
12 (15%) had their conditions managed with medical therapy. Thoracic endovascular aortic repair was associated
with lower in-hospital or 30-day mortality (n ¼ 2, 4%) than conventional therapy (open surgical repair n ¼ 8,
40%, medical therapy, n¼ 4, 33%, P¼ .006). Patients in group A (thoracic endovascular aortic repair) continued
to show significantly improved survival at 1, 3, and 5 years (group A: 82%, 79%, and 79% vs group B: 58%,
52%, and 44%, P ¼ .008).
Conclusions: Thoracic endovascular aortic repair for acute complicated type B dissection is associated with
superior early outcome and improved midterm survival relative to conventional therapy. Longer follow-up dem-
onstrating survival benefit is needed before definitive conclusion can be made. (J Thorac Cardiovasc Surg
2010;140:S109-15)Management of acute type B aortic dissection remains
a clinical challenge. In acute type B aortic dissection with
life-threatening complications, conventional open surgical
and medical therapies continue to be associated with signif-
icant mortality risk, as high as 50%.1-5 Since its initial
introduction and subsequent US Food and Drug
Administration approval, thoracic endovascular aortic
repair (TEVAR) has emerged as a new option for the
treatment of acute type B aortic dissection. Although the
role of TEVAR in the treatment of uncomplicated acute
type B aortic dissection remains controversial, TEVAR
has emerged as a viable option in the treatment of acute
type B aortic dissection associated with life-threateninge Divisions of Cardiovascular Surgerya and Vascular and Endovascular
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The Journal of Thoracic and Cardcomplications. Early experience has demonstrated dramati-
cally improved perioperative results, with 30-day mortality
less than 10%.6,7 Comparison with conventional open
surgical and medical therapies, however, remains limited.
Furthermore, data demonstrating survival benefit beyond
the initial perioperative period remain lacking.
Because of the dramatic improvement in outcome in our
early series,6 TEVAR has become the preferred therapy
for acute type B aortic dissection with life-threatening com-
plications at our institution. In this study, we retrospectively
compared the early perioperative outcome of complicated
acute type B aortic dissection treated with TEVAR versus
conventional open surgical and medical therapies in a con-
temporary period. Furthermore, follow-up data were
analyzed to compare survival benefit of TEVAR versus
conventional surgical and medical therapies.MATERIALS AND METHODS
A retrospective review of the thoracic aortic surgery clinical database at
the University of Pennsylvania was performed from June 2002 to January
2010. Electronic and paper charts were reviewed for preoperative patient
and demographic characteristics, clinical presentation, characteristics of dis-
section, indications for surgery, perioperative events and complications, and
in-hospital mortality. Follow-up mortality data were collected by reviewing
the Social Security Death Index.
From 2002 to 2010, a total of 195 patients were admitted to our institu-
tion with the diagnosis of Stanford type B aortic dissection. In accordanceiovascular Surgery c Volume 140, Number 6S S109
Abbreviation and Acronym
TEVAR ¼ thoracic endovascular aortic repair
Aortic Symposium 2010 Zeeshan et alwith the Stanford classification, type B aortic dissection was defined as any
nontraumatic dissection that involved the descending thoracic aorta with the
tear site distal to the left subclavian artery. Acute dissections were defined
as those with delay from onset of symptoms to presentation shorter than
14 days.8,9 Diagnosis was based on history, physical examination, and
imaging by echocardiography, computed tomography, or magnetic
resonance imaging. Of the 195 patients identified, 147 patients had acute
type B dissection. Complicated acute type B aortic dissections, as defined
by the presence of rupture, malperfusion, extension of dissection, or
shock, were seen in 77 patients. In this group of complicated acute type B
aortic dissections, 45 patients (59%, group A) were treated with TEVAR;
the remaining 32 patients (41%, group B) were treated with conventional
open surgical and medical therapies (Table 1).
The choice of therapy was made according to availability of the endog-
rafts and anatomic suitability for TEVAR. Before the US Food and Drug
Administration approval of Gore TAG endoprosthesis (W.L. Gore Inc,
Flagstaff, Ariz) in 2005, most patients were treated with conventional
open surgical and medical therapies. After 2005, most patients, all of
whommet anatomic criteria, were treated with TEVAR. Patients considered
to be prohibitively high risk for open surgical repair and unsuitable for
endovascular repair were treated with medical therapy alone.
The institutional review board at the University of Pennsylvania
approved the study and waived the need for patient consent.
Surgical Technique
All patients underwent intervention within 14 days of initial presenta-
tion. For patients requiring conventional open surgical repair, a standard
thoracoabdominal approach was used. Intraoperative neural monitoring
was performed with lumbar drainage when possible. Hypothermic circula-
tory arrest was used when an open proximal anastomosis was necessary.
Affected descending thoracic aortic segment was replaced with a Dacron
polyester fabric graft.10 In a minority of cases, extra-anatomic bypasses
were performed when limb malperfusion was the indication for surgical
intervention.
For patients treated with TEVAR, an algorithmic approach was used, and
our technique has been previously described.6 In brief, the steps of the proce-
dure included (1) establishment ofwire access in the true lumenwith intravas-
cular ultrasonographic confirmation, (2) coverage of primary tear site with
endograft, (3) true lumen expansion, (4) restoration of distal aortic blood
flow, and (5) correction of rupture or malperfusion with adjunct stenting.
For patients deemed at prohibitively high risk to undergo open surgical
repair without anatomy suitable to TEVAR, medical therapy with strict
blood pressure control and anti-impulse therapy was performed with 1 or
more intravenous antihypertensive agents. Systolic and mean blood pres-
sures were maintained below 120 and 70 mm Hg, respectively.11 A similar
antihypertensive regimen was used perioperatively for all patients undergo-
ing open or endovascular surgery.12
Assessment of Aortic Remodeling, Aorta-Related
Events, and Survival
Evidence of aortic remodeling was observed by reviewing latest avail-
able post intervention computed tomographic angiography.13 Observations
of the true and false lumen were made at the proximal descending thoracic
aorta (at the level of the endograft) and at the distal thoracoabdominal aorta.
Patients in the TEVAR group were also followed up postoperatively
to evaluate aorta-related events and survival. Aorta-related events were
defined as follows: (1) aortic reintervention (open or endovascular),S110 The Journal of Thoracic and Cardiovascular Sur(2) progression of dissection, (3) new rupture or malperfusion, (4) endoleak,
and (5) aorta-related death.
Statistical Analysis
All continuous variables are expressed as mean  SD. Statistical
methods were applied to compare group A (TEVAR) with group B (conven-
tional open surgical and medical therapies) Univariate analysis was
performed with Fisher’s Exact test for categoric variables. Survival was
analyzed with Kaplan–Meier survival curves. Probability values were
calculated with the log-rank test. SPSS software version 15.0 (SPSS Inc,
an IBM Company, Chicago, Ill) was used for all calculations.
RESULTS
In the total cohort of 77 patients with complicated acute
type B aortic dissection, 45 patients underwent TEVAR
(group A) and 32 patients underwent conventional surgical
and medical therapies (group B). Preoperative characteris-
tics of patients, presentation, and indications for intervention
were similar between groups (Table 1).
All patients were operated on within 14 days of presenta-
tion. In group A, 26 patients (58%) underwent TEVAR
within 24 hours of presentation. In group B, 10 patients
(50%) underwent open repair within 24 hours of presenta-
tion. Aortic rupture and distal malperfusion were the major
indications for operation in both groups (Table 1).
Stent Grafts and Adjunct Procedures
Three stent grafts were used for the endovascular treat-
ment. Gore TAG thoracic endoprosthesis was used in most
cases (n ¼ 37, 75%). The Medtronic Talent thoracic endo-
prosthesis (Medtronic Vascular, Santa Clara, Calif) and the
Zenith ELSE (Cook Inc, Bloomington, Ind) were each
used in 4 cases (8%).
In addition, 18 patients treated with TEVAR had 1 or
more adjunct procedures performed. These adjunct proce-
dures included distal abdominal aortic and peripheral iliofe-
moral stenting (n ¼ 12), mesenteric or renal artery stenting
(n ¼ 4), and extra-anatomic bypass (femorofemoral bypass
n ¼ 1, left carotid–left subclavian artery bypass n ¼ 1).
Hospital Stay and Complications
Although the difference was not statistically significant,
TEVAR was associated with slightly shorter hospital stay
than was conventional therapy (Table 2). Postoperative com-
plications were compared between the groups (Table 2). The
risk of postoperative complications was not statistically dif-
ferent between groups; however, of the 12 patients treated
medically, 9 (75%) presented with isolated renal malperfu-
sion and subsequent renal failure. Of these 9 patients, 7
eventually either died or required long-term hemodialysis.
Aortic Remodeling (Figure 1)
Surveillance postoperative computed tomographic angiog-
raphy was performed in 39 of 43 patients (90%) who
survived the perioperative period. Computed tomographicgery c December 2010
TABLE 1. Patient characteristics and presentation for complicated acute type B aortic dissection
Group A (n ¼ 45, 59%) Group B (n ¼ 32, 41%)
TEVAR Open surgical repair Medical management P value*
Preoperative characteristics
Age (y, mean  SD) 59.1  13.2 56.0  18.8 67.4  11.7 .803
Sex (no. male) 32 (71%) 16 (80%) 6 (50%) .544
Coronary artery disease 5 (11%) 3 (15%) 5 (42%) .131
Myocardial infarction/angina 4 (9%) 3 (15%) 5 (42%) .065
Congestive heart failure 5 (11%) 3 (15%) 2 (17%) .733
Arrhythmias 3 (7%) 3 (15%) 1 (8%) .441
Hypertension 39 (87%) 11 (55%) 11 (92%) .146
Smoking 21 (47%) 10 (50%) 6 (50%) .82
Chronic obstructive pulmonary disease 7 (16%) 3 (15%) 4 (33%) .555
Cerebrovascular accident 2 (4%) 0 (0%) 3 (25%) .644
Transient ischemic attack 0 (0%) 2 (10%) 1 (8%) .068
Diabetes 8 (18%) 1 (5%) 1 (8%) .18
Chronic renal insufficiency 6 (13%) 3 (15%) 5 (42%) .314
Abdominal aortic aneurysm 4 (9%) 3 (15%) 2 (17%) .477
Thoracic aortic aneurysm 3 (7%) 2 (10%) 0 (0%) .659
Peripheral arterial disease 3 (7%) 2 (10%) 2 (17%) .441
Presentation
Onset to repair
<1 d 26 (58%) 10 (50%) 4 (33%)
1-14 d 19 (42%) 10 (50%) 8 (67%)
Rupture 17 (38%) 9 (45%) 3 (25%) 0.586
Malperfusion 34 (76%) 10 (50%) 8 (67%) 0.144
Hypertension 1 (2%) 2 (10%) 3 (25%) 0.405
Refractory pain 4 (9%) 2 (10%) 0 (0%) 0.511
Retrograde extension 1 (2%) 3 (15%) 0 (0%) .302
False lumen expansion 5 (11%) 1 (5%) 1 (8%) .693
Shock 2 (4%) 2 (10%) 0 (0%) .644
All data are numbers and percentages of patients unless otherwise noted. TEVAR, Thoracic endovascular aortic repair. *P value was calculated with Fisher’s Exact test comparing
group A (thoracic endovascular aortic repair) versus group B (conventional open surgical repair and medical management).
Zeeshan et al Aortic Symposium 2010angiographic review demonstrated aortic remodeling in 30
of 39 patients (77%) with complete thrombosis of the false
lumen in the descending thoracic aorta at the level of the en-
dograft. Complete aortic remodeling with thrombosis of false
lumen of the entire thoracoabdominal aorta was seen in 11TABLE 2. Mortality, hospital stay, and postoperative complications after
Group A
TEVAR Ope
Mortality and hospital stay
Mortality at 30 d 2 (4%)
Hospital stay (d, mean  SD) 15.9  11.4
Postoperative complications
Cardiac complications 3 (7%)
Postoperative myocardial infarction 1 (2%)
Acute renal failure 19 (42%)
Requirement for dialysis 4 (9%)
Gut ischemia 4 (9%)
Respiratory failure 9 (20%)
Paraplegia 6 (13%)
Stroke 3 (7%)
All data are numbers and percentages of patients unless otherwise noted. TEVAR, Thoracic
group A (thoracic endovascular aortic repair) versus group B (conventional open surgical r
The Journal of Thoracic and Cardpatients (28%). Thrombosis of false lumen at the level of
the endograft with persistent false lumen patency at the level
of the distal thoracoabdominal aorta was seen in 19 patients
(49%). In the remaining 9 patients (23%), persistent patent
false lumen in the entire thoracoabdominal aorta was seen.thoracic endovascular aortic repair and conventional treatment
Group B
n surgical repair Medical management P value*
8 (40%) 4 (33%) .006
16.6  14.8 15.9  10.2 .865
3 (15%) 2 (17%) .265
1 (5%) 1 (8%) .373
4 (20%) 9 (75%) .539
3 (15%) 2 (17%) .304
1 (5%) 1 (8%) .621
2 (10%) 3 (25%) .791
2 (10%) 1 (8%) .728
0 (0%) 2 (17%) .659
endovascular aortic repair. *P value was calculated with Fisher’s Exact test comparing
epair and medical management).
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FIGURE 1. Computed tomographic angiography demonstrating complete thrombosis and obliteration of false lumen in entire thoracoabdominal aorta
(A, B), thrombosis and obliteration of false lumen in thoracic aorta but patent false lumen in abdominal aorta (C, D), and patent false lumen in entire thor-
acoabdominal aorta (E, F).
Aortic Symposium 2010 Zeeshan et alEarly Outcome and Survival (Figure 2)
The mean patient follow-up was 37 months, ranging from
2 months to 7 years. In-hospital or 30-day mortality in group
A was significantly lower than that in group B (P ¼ .006;
Table 2). Kaplan–Meier analysis demonstrated significant
improvement in survival for patients treated with TEVAR
at 1,3, and 5 years (group A 82%, 79%, and 79% vs group
B 58%, 52%, and 44%, respectively, P ¼ .008).
In the TEVAR group, there were 2 early deaths. The first
patient had a pulseless electrical activity arrest 3 days after
TEVAR. The second patient had presented with left-sided
stroke before TEVAR and subsequently had spinal cord is-
chemia after emergency TEVAR. That patient eventually
died of multisystem organ failure.
In the medically managed group, there were 4 early
deaths. The first patient presented with mesenteric ischemia
and required a bowel resection. That patient subsequentlyS112 The Journal of Thoracic and Cardiovascular Surhad overwhelming sepsis with thrombocytopenia and devel-
opment of multisystem organ failure. The second death was
that of a patient deemed at prohibitively high risk for open
surgical repair. Care was withdrawn at the family’s request.
The third patient was transferred to a subacute facility after
initiation of medical therapy. That patient never left the
medical facility, subsequently dying within 30 days of pre-
sentation. The cause of death is not available.
Freedom From Aorta-Related Events
In the TEVAR group, there were two aorta-related deaths,
as described previously. Three patients had retrograde dissec-
tions develop and required open proximal aortic and arch
repair. Two additional patients had rapid expansion of the
proximal aorta and arch requiring ascending aortic repair in-
cluding a valve-sparing reimplantation aortic root replace-
ment. Another patient had an endoleak develop, requiringgery c December 2010
FIGURE 2. Kaplan–Meier survival curve demonstrating improved midterm survival with thoracic endovascular aortic repair (TEVAR) versus conventional
open surgical and medical management (log-rank test, P ¼ .008).
Zeeshan et al Aortic Symposium 2010endovascular reintervention. Additionally, 1 patient had thor-
acoabdominal aneurysmal degeneration of the distal aorta
that required open repair. Another patient subsequently un-
derwent an endovascular abdominal aortic aneurysm repair.
DISCUSSION
The treatment of complicated acute typeB aortic dissection
has remained a clinical challenge. Recent studies have
described the safety and efficacy of endovascular repair for
the treatment of complicated acute type B aortic dissec-
tion,6,14 with encouraging results in the early perioperative
period; however, few studies have compared clinical
outcomes between conventional open surgical and medical
therapies and the use of TEVAR. In our study, the
endovascular repair of complicated acute type B aortic
dissection was associated with an acceptable operative
mortality of 4%. Furthermore, our contemporary
comparison with conventional open surgical and medical
therapies confirms significant improvement in patient
outcome. This is not surprising in light of the high
morbidity and mortality associated with conventional open
and medical therapy in other series.1-5 Other centers have
also demonstrated the safety and effectiveness of TEVAR
for the repair of acute complicated type B aortic
dissection.1,6,7,15,16 Younes and colleagues7 reported an over-
all 30-day mortality of 5.5% after TEVAR. Khoynezhad and
associates14 reported 82% and 78%mortalities 1 and 5 years
after TEVAR. Fattori and colleagues1 reported 33.9% mor-
tality with open surgery for acute type B aortic dissection ver-
sus 10.6% after endovascular repair. A recent meta-analysisThe Journal of Thoracic and CardfromChina reported an overall mortality of 2.6% 0.1% af-
ter TEVAR for acute type B aortic dissection.17 These studies
serve as mounting evidence that the introduction of TEVAR
has resulted in a new paradigm in the treatment of compli-
cated acute type B aortic dissection.
In our series, improvement in perioperative outcome also
appears to have translated into continued improvement in
midterm survival. For patients treated with TEVAR,
5-year survival in our series remains encouraging at 79%.
This is consistent with a recent study reported by Khoynez-
had and associates,14 which demonstrated a 5-year survival
of 78%. Furthermore, in our series 5-year survival in the
conventional surgical and medical therapies group is 44%,
which is both disappointing and significantly lower than
that after TEVAR . Although our experience represents
a smaller cohort, it remains consistent with larger series
that used the International Registry of Acute Aortic Dissec-
tion database.1,5 These 2 larger series suggest that for
complicated acute type B aortic dissection, endovascular
repair is associated both with significantly improved early
outcome and with midterm survival benefit at 5-year
follow-up. Certainly, longer follow-up is needed before
definitive conclusions can be made.
Aortic Remodeling
The concept of aortic remodeling remains debatable;
however, our data do support a potential positive effect of
TEVAR on aortic remodeling. Most patients treated with
TEVAR (30 of 39, 77%) demonstrated complete thrombosis
and obliteration of the false lumen in the thoracic aorta at theiovascular Surgery c Volume 140, Number 6S S113
Aortic Symposium 2010 Zeeshan et allevel of the endograft. Interestingly, the thrombosis rate is
very similar to our experience with the use of adjunct stent-
ing in the distal thoracic aorta during acute type A dissection
repair.18,19 Most patients, however, have continued to have
a patent false lumen in the distal thoracic and abdominal
aorta despite complete remodeling in the proximal thoracic
aorta. Whether this remodeling alters the natural history of
aneurysmal degeneration of the distal thoracoabdominal
aorta remains unanswered and will require longer follow-
up. Interestingly, although it was a study examining the
role of TEVAR in uncomplicated type B aortic dissection,
the INvestigation of STEnt grafts in Aortic Dissection (IN-
STEAD) trial also demonstrated positive aortic remodeling
with TEVAR, consistent with our findings.15 Although the
study did not demonstrate survival benefit with TEVAR,
91.3% patients had complete false lumen thrombosis and
showed morphologic evidence of aortic remodeling. In
contrast, medical treatment alone did not result in any false
lumen shrinkage or thrombus formation in most cases. The
lack of a survival benefit with TEVAR despite positive aor-
tic remodeling needs further inquiry. One possible explana-
tion is that our study is small and therefore insufficiently
powered to answer this question, particularly when the con-
trol group (medical therapy for acute uncomplicated acute
type B aortic dissection) has such a low mortality. Whether
aortic remodeling is related or responsible for the improved
midterm survival in our study will require further investiga-
tion, likely in a large, multicenter study.
Off-Label Use
Although many centers have reported the use of TEVAR
in acute type B aortic dissection, we must caution that, at
least in the United States, this remains an off-label use.
Our institution has therefore remained cautious with the
use of TEVAR in acute type B aortic dissection. In this series,
only acute type B aortic dissectionwith life-threatening com-
plications, including malperfusion, rupture, shock, or pend-
ing rupture with rapid aneurysmal enlargement, is currently
treated with TEVAR. We remain hesitant regarding the use
of TEVAR in patients with stable uncomplicated acute
type B aortic dissection. These presentations or clinical sce-
narios include refractory pain and uncontrolled hypertension
in uncomplicated acute type B aortic dissection. Only for pa-
tients with factors associated with increased risk of poor out-
come do we reluctantly consider treatment with TEVAR.
These include increased false lumen index (false lumen
>22 mm), aneurysmal characteristic with total diameter
greater than 40 mm, and an elevated fusiform index.20,21,22
Limitations
We recognize that our study has several limitations. First,
it is a retrospective, nonrandomized, observational, single-
institution study. Second, the choice of therapy was biased
by the availability of endograft technology. Most patientsS114 The Journal of Thoracic and Cardiovascular Surtreated with TEVAR were treated after the US Food and
Drug Administration approval in 2005. Before 2005,
patients were treated with open surgical therapy unless the
surgeons considered the patient to be at prohibitively high
risk, and endografts were available under extraordinary cir-
cumstances. Nonetheless, the open surgical cohort remains
a contemporary comparative group. In addition, medical
management for acute complicated type B aortic dissection
was undertaken despite its known association with poor out-
come from other historical studies. In our series, these pa-
tients were not treated surgically because the risk was felt
to be prohibitively high. Interestingly in our small series,
medical management of complicated acute type B aortic dis-
section was associated with a 33% early mortality. At initial
examination, our result appears relatively low compared to
other historical studies; however, further examination again
reveals a potential bias and perhaps a hesitancy to proceed
with surgical intervention because of its association with
poor outcome. In the 9 of 12 patients (75%) with compli-
cated acute type B aortic dissection treated medically, iso-
lated renal malperfusion with acute renal failure was the
presentation. Of these 9 patients, 7 eventually died or re-
quired long-term, chronic hemodialysis, again reflective of
the poor outcome with medical management in patients
with complicated acute type B aortic dissection.
CONCLUSIONS
With the introduction of TEVAR, the management of
acute type B aortic dissection has evolved dramatically in
the last decade. Mounting evidence is supporting the use
of TEVAR, particularly for acute type B aortic dissection
with life-threatening complications. Our study, a compara-
tive study examining the treatment of complicated acute
type B aortic dissection in the eras before and after the intro-
duction of TEVAR, further strengthens the evidence for
favorable outcome of TEVAR in complicated acute type
B aortic dissection relative to the conventional treatment
paradigm of open surgical and medical therapies. At our in-
stitution, we firmly believe that TEVAR has emerged as the
preferred treatment strategy, representing a new surgical par-
adigm in the treatment of complicated acute type B aortic
dissection. Furthermore, our study also suggests that the
benefit is conveyed beyond the initial perioperative period,
as demonstrated by significantly improved 5-year survival
with evidence of aortic remodeling.
We thank Patrick Moeller and WilliamMoser for their help with
the Penn Thoracic Aortic Database and data management.
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